303 related articles for article (PubMed ID: 19967148)
1. Fibrin network structure and clot mechanical properties are altered by incorporation of erythrocytes.
Gersh KC; Nagaswami C; Weisel JW
Thromb Haemost; 2009 Dec; 102(6):1169-75. PubMed ID: 19967148
[TBL] [Abstract][Full Text] [Related]
2. Sensing adhesion forces between erythrocytes and γ' fibrinogen, modulating fibrin clot architecture and function.
Guedes AF; Carvalho FA; Domingues MM; Macrae FL; McPherson HR; Santos NC; Ariёns RAS
Nanomedicine; 2018 Apr; 14(3):909-918. PubMed ID: 29410160
[TBL] [Abstract][Full Text] [Related]
3. The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics.
Gersh KC; Zaitsev S; Muzykantov V; Cines DB; Weisel JW
J Thromb Haemost; 2010 May; 8(5):1066-74. PubMed ID: 20149071
[TBL] [Abstract][Full Text] [Related]
4. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
5. Probing interactions of red blood cells and contracting fibrin platelet clots.
Sun Y; Le H; Lam WA; Alexeev A
Biophys J; 2023 Nov; 122(21):4123-4134. PubMed ID: 37598293
[TBL] [Abstract][Full Text] [Related]
6. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking.
Byrnes JR; Duval C; Wang Y; Hansen CE; Ahn B; Mooberry MJ; Clark MA; Johnsen JM; Lord ST; Lam WA; Meijers JC; Ni H; Ariëns RA; Wolberg AS
Blood; 2015 Oct; 126(16):1940-8. PubMed ID: 26324704
[TBL] [Abstract][Full Text] [Related]
7. The association between human blood clot analogue computed tomography imaging, composition, contraction, and mechanical characteristics.
Cruts JMH; Giezen JA; van Gaalen K; Beurskens R; Ridwan Y; Dijkshoorn ML; van Beusekom HMM; Boodt N; van der Lugt A; de Vries JJ; de Maat MPM; Gijsen FJH; Cahalane RME
PLoS One; 2023; 18(11):e0293456. PubMed ID: 37956141
[TBL] [Abstract][Full Text] [Related]
8. Lytic resistance of fibrin containing red blood cells.
Wohner N; Sótonyi P; Machovich R; Szabó L; Tenekedjiev K; Silva MM; Longstaff C; Kolev K
Arterioscler Thromb Vasc Biol; 2011 Oct; 31(10):2306-13. PubMed ID: 21737785
[TBL] [Abstract][Full Text] [Related]
9. Computational imaging analysis of fibrin matrices with the inclusion of erythrocytes from homozygous SS blood reveals agglomerated and amorphous structures.
Averett RD; Norton DG; Fan NK; Platt MO
J Thromb Thrombolysis; 2017 Jan; 43(1):43-51. PubMed ID: 27664114
[TBL] [Abstract][Full Text] [Related]
10. Impact of γ'γ' fibrinogen interaction with red blood cells on fibrin clots.
Guedes AF; Carvalho FA; Domingues MM; Macrae FL; McPherson HR; Sabban A; Martins IC; Duval C; Santos NC; Ariëns RA
Nanomedicine (Lond); 2018 Oct; 13(19):2491-2505. PubMed ID: 30311540
[TBL] [Abstract][Full Text] [Related]
11. A monoclonal antibody to the fibrinogen gamma-chain alters fibrin clot structure and its properties by producing short, thin fibers arranged in bundles.
Scheiner T; Jirousková M; Nagaswami C; Coller BS; Weisel JW
J Thromb Haemost; 2003 Dec; 1(12):2594-602. PubMed ID: 14675095
[TBL] [Abstract][Full Text] [Related]
12. Phase transitions during compression and decompression of clots from platelet-poor plasma, platelet-rich plasma and whole blood.
Liang X; Chernysh I; Purohit PK; Weisel JW
Acta Biomater; 2017 Sep; 60():275-290. PubMed ID: 28694237
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous presence of hypercoagulation and increased clot lysis time due to IL-1β, IL-6 and IL-8.
Bester J; Matshailwe C; Pretorius E
Cytokine; 2018 Oct; 110():237-242. PubMed ID: 29396046
[TBL] [Abstract][Full Text] [Related]
14. Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent.
Gersh KC; Zaitsev S; Cines DB; Muzykantov V; Weisel JW
Blood; 2011 May; 117(18):4964-7. PubMed ID: 21389322
[TBL] [Abstract][Full Text] [Related]
15. Fibrin structure and concentration alter clot elastic modulus but do not alter platelet mediated force development.
Carr ME; Carr SL
Blood Coagul Fibrinolysis; 1995 Feb; 6(1):79-86. PubMed ID: 7795157
[TBL] [Abstract][Full Text] [Related]
16. Surfactant incorporation markedly alters mechanical properties of a fibrin clot.
Günther A; Kalinowski M; Rosseau S; Seeger W
Am J Respir Cell Mol Biol; 1995 Dec; 13(6):712-8. PubMed ID: 7576709
[TBL] [Abstract][Full Text] [Related]
17. Clot friction variation with fibrin content; implications for resistance to thrombectomy.
Gunning GM; McArdle K; Mirza M; Duffy S; Gilvarry M; Brouwer PA
J Neurointerv Surg; 2018 Jan; 10(1):34-38. PubMed ID: 28044009
[TBL] [Abstract][Full Text] [Related]
18. Fibrin mechanical properties and their structural origins.
Litvinov RI; Weisel JW
Matrix Biol; 2017 Jul; 60-61():110-123. PubMed ID: 27553509
[TBL] [Abstract][Full Text] [Related]
19. Fibrin clot properties are altered in patients with chronic obstructive pulmonary disease. Beneficial effects of simvastatin treatment.
Undas A; Kaczmarek P; Sladek K; Stepien E; Skucha W; Rzeszutko M; Gorkiewicz-Kot I; Tracz W
Thromb Haemost; 2009 Dec; 102(6):1176-82. PubMed ID: 19967149
[TBL] [Abstract][Full Text] [Related]
20. Incorporation of fibrin molecules containing fibrinopeptide A alters clot ultrastructure and decreases permeability.
Flood VH; Nagaswami C; Chernysh IN; Al-Mondhiry HA; Weisel JW; Farrell DH
Br J Haematol; 2007 Jul; 138(1):117-24. PubMed ID: 17555455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
